Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Outcomes of Lung Transplant Recipients Hospitalized With COVID-19 Infection in the Post-Acute Pandemic Era: A Nationwide Inpatient Analysis in the United States.

Created on 26 Aug 2026

Authors

Dawlat Khan, Hammad Chaudhry, Dawood Shehzad, Haddaya Umar, David Wachira, Kelly M Pennington, Gwen Thompson

Published in

Transplantation proceedings. Aug 25, 2026. Epub Aug 25, 2026.

Abstract

Lung transplant recipients (LuTRs) remain highly susceptible to severe COVID-19 due to chronic immunosuppression and graft vulnerability. Although early pandemic data described high morbidity and mortality, contemporary nationwide evidence from the post-acute pandemic period is limited.
Using ICD-10-CM codes, we identified 9,276 adult LuTR hospitalizations in NRD-2022, of which 12.8% (n = 1185) had COVID-19. Primary outcomes included in-hospital mortality, CLAD, and 90-day readmission. Secondary outcomes included ARDS, invasive mechanical ventilation (IMV), acute kidney injury (AKI), ICU admission, shock, thromboembolic events, and resource utilization (length of stay [LOS], total charges). Multivariable logistic and linear regression models adjusted for patient- and hospital-level covariates.
COVID-19-positive LuTRs had significantly higher in-hospital mortality than non-COVID LuTRs (aOR 3.97; p < .001) and markedly increased odds of CLAD (aOR 10.55; p < .001). They also demonstrated higher odds of ARDS (aOR 9.36; p < .001), IMV (aOR 3.07; p < .001), ICU admission (aOR 2.82; p < .001), shock (aOR 1.85; p < .001), AKI (aOR 1.53; p < .001), and superimposed bacterial pneumonia (aOR 1.75; p < .001). Rates of tracheostomy, VV-ECMO use, pulmonary embolism, and deep venous thrombosis did not differ significantly. Ninety-day readmission rates were similar (aOR 1.06; p = .41). COVID-19 hospitalizations were associated with longer LOS (+3.72 days; p = .001) and higher total charges (+$59,350; p = .012).
In the post-acute pandemic era, COVID-19 continues to impose a substantial clinical and economic burden on LuTRs, with elevated risks of mortality, CLAD, respiratory failure, multiorgan dysfunction, and greater resource utilization. Continued vigilance, preventive strategies, and tailored management remain essential for this high-risk population.

PMID:
42642232
Bibliographic data and abstract were imported from PubMed on 26 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement